Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricular remodeling in rats with myocardial infarct-induced heart failure

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 5, 2010, Pages 506-512

  Xu, Kai ^a   George, Isaac ^b   Klotz, Stefan ^b   Hay, Ilan ^b   Xydas, Steve ^b   Zhang, Geping ^b   Cerami, Anthony ^c   Wang, Jie ^b,d  

^a Shenyang Northern Hospital   (China)

^b Columbia University ^*  (United States)

^c Warren Pharmaceuticals Inc   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

drug administration; heart failure; myocardial infarction; pressure volume relation; ventricular remodeling

Indexed keywords

CARBAMYLATED ERYTHROPOIETIN; ERYTHROPOIETIN; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIASTOLE; ECHOCARDIOGRAPHY; EX VIVO STUDY; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE PERFORMANCE; HEMODYNAMICS; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; TAIL;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; ERYTHROPOIETIN; HEART FAILURE; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 78650181656     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f4f05a     Document Type: Article

References (33)

1. Henry DH, Spivak JL. Clinical use of erythropoietin. Curr Opin Hematol. 1995;2:118-124.
2. Romsi P, Rönkä E, Kiviluoma K, et al. Potential neuroprotective benefits of erythropoietin during experimental hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 2002;124:714-723. (Pubitemid 36025350)
3. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526-10531.
4. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA. 2003;100:6741-6746.
5. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-4806.
6. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003;100:11612-11617.
7. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007.
8. Sterin-Borda L, Barcelo AC, Bozzini CE. Erythropoietin improves cardiac contractility in post-hypoxic mice. Br J Haematol. 2003;121:180-186.
9. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem. 2004;279:20655-20662.
10. Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc Drugs Ther. 2005;19:333-336.
11. Miki T, Miura T, Yano T, et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther. 2006;317:68-75.
12. Fiordaliso F, Chimenti S, Staszewsky L, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2005;102:2046-2051.
13. Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovasc Electrophysiol. 2001;12:369-381.
14. Bolli R, Becker L, Gross G, et al. Myocardial protection at a crossroads. Circ Res. 2004;95:125-134.
15. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcomes of patients with early (,2h), intermediate (2-4h), and late (.4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2002;23:550-557.
16. Ito H, Takaki M, Yamaguchi H, et al. Left ventricular volumetric conductance catheter for rats. Am J Physiol. 1996;270:H1509-H1514.
17. Rabkin DG, Jia CX, Cabreriza SE, et al. A novel arresting solution for study of postmortem pressure-volume curves of the rat left ventricle. J Surg Res. 1998;80:221-228.
18. Hale SL, Sesti C, Kloner RA. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol. 2005;46:211-215.
19. Mori S, Sawada T, Okada T, et al. Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat. Surgery. 2008;143:556-565.
20. Gao E, Boucher M, Chuprun JK, et al. Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol. 2007;293:H60-H68.
21. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305:239-242.
22. Joyeux-Faure M, Godin-Ribout D, Ribout C. Erythropoietin and myocardial protection: what's new. Fundam Clin Pharmacol. 2005;19: 439-446.
23. Joyeux-Faure M, Ramond A, Beguin PC, et al. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fundam Clin Pharmacol. 2006;20:51-56.
24. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 2003;108:79-85.
25. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473-479.
26. Beleslin-Cokic BB, Cokic VP, Yu X, et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004;104:2073-2080.
27. Fantacci M, Biancardi P, Caretti A, et al. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci USA. 2006;103:17531-17536.
28. Liu X, Xie W, Liu P, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia reperfusion. Life Sci. 2006;78:2255-2264.
29. Tramontano AF, Muniyappa R, Black AD, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308: 990-994.
30. Wang L, Zhang Z, Wang Y, et al. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35:1732-1737.
31. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res. 2002;64: 326-333.
32. Westerbrink BD, Ruifrok WT, Voors AA, et al. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovasc Res. 2010;87:30-39.
33. Lipsic E, van der Meer P, Voors AA, et al. A Single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006;20:135-141.